Collateral sensitivity to gemcitabine (2′,2′-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines

This publication has 30 references indexed in Scilit:

• Decreased resistance to gemcitabine (2′,2′-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase
  Biochemical Pharmacology, 1999
• Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines
  International Journal of Cancer, 1996
• P-Glycoprotein — A Marker of Cancer-Cell Behavior
  New England Journal of Medicine, 1995
• Increased ratio between deoxycytidine kinase and thymidine kinase 2 in CLL lymphocytes compared to normal lymphocytes
  Leukemia Research, 1995
• Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC)
  Annals of Oncology, 1994
• 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines
  Biochemical Pharmacology, 1993
• Intratumoral pharmacokinetic analysis by 19F-magnetic resonance spectroscopy and cytostatic in vivo activity of gemcitabine (dFdC) in two small cell lung cancer xenografts
  Annals of Oncology, 1993
• 2'-Deoxy-2'-methylenecytidine and 2'-deoxy-2',2'-difluorocytidine 5'-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase
  Journal of Medicinal Chemistry, 1991
• Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs
  Biochemical and Biophysical Research Communications, 1991
• Human T-lymphoblast deoxycytidine kinase: purification and properties
  Biochemistry, 1989